How I treat older patients with ALL

Blood

Volumn 122, Issue 8, 2013, Pages 1366-1375

  Gökbuget, Nicola ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIFUNGAL AGENT; ASPARAGINASE; BENDAMUSTINE; BLINATUMOMAB; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; FIBRINOGEN; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; HYDROXYUREA; IDARUBICIN; IMATINIB; LACTATE DEHYDROGENASE; MERCAPTOPURINE; METHOTREXATE; NELARABINE; NILOTINIB; NON PRESCRIPTION DRUG; PREDNISONE; PURINE DERIVATIVE; PYRROLE DERIVATIVE; RITUXIMAB; STEROID; VINCRISTINE; VINDESINE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; AGE; ALTERNATIVE MEDICINE; ANTIBIOTIC PROPHYLAXIS; ANTIGEN EXPRESSION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CARDIOTOXICITY; CHARLSON COMORBIDITY INDEX; CHRONIC LUNG DISEASE; CLINICAL DECISION MAKING; CLINICAL FEATURE; COMORBIDITY; CONSOLIDATION CHEMOTHERAPY; CONTINUOUS INFUSION; CYTOGENETICS; CYTOPENIA; DAILY LIFE ACTIVITY; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DIET SUPPLEMENTATION; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; GERIATRIC ASSESSMENT; GERIATRIC DISORDER; HEART DISEASE; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; IMMUNOPHENOTYPING; INDUCTION CHEMOTHERAPY; INFECTION; KIDNEY FAILURE; LACTATE BLOOD LEVEL; LEUKEMIA RELAPSE; LEUKOCYTE COUNT; LIFE EXPECTANCY; LIVER TOXICITY; LONG TERM SURVIVAL; LOW DRUG DOSE; MOLECULAR DIAGNOSTICS; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUROTOXICITY; OSTEOPOROSIS; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POLYNEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; RECURRENCE RISK; REDUCED INTENSITY CONDITIONING; SELF MEDICATION; SUBDURAL HEMATOMA; THROMBOCYTE COUNT; VASCULAR DISEASE; AGED; CLINICAL TRIAL (TOPIC); METHODOLOGY; ONCOLOGY; PALLIATIVE THERAPY; PROGNOSIS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COMORBIDITY; GERIATRIC ASSESSMENT; HUMANS; MEDICAL ONCOLOGY; PALLIATIVE CARE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; QUALITY OF LIFE; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84886815732     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-07-379016     Document Type: Article

References (98)

1. Altekruse SF, Kosary CL, Krapcho M, et al. Seer Cancer Statistics Review 1975-2007. National Cancer Institute, Bethesda, MD, http://seer.cancer.gov/csr/ 1975-2010/. 2007.
2. Smith BD, Smith GL, Hurria A, Hortobagyi G.N., Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009; 27(17): 2758-2765.
3. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011; 29(5): 532-543.
4. Pagano L, Mele L, Casorelli I., Fianchi L, Di Febo A, Leone G. Acute lymphoblastic leukemia in the elderly. A twelve-year retrospective, single center study. Haematologica. 2000; 85(12): 1327-1329. (Pubitemid 32063706)
5. Legrand O, Marie JP, Marjanovic Z, et al. Prognostic factors in elderly acute lymphoblastic leukaemia. Br J Haematol. 1997; 97(3): 596-602. (Pubitemid 27261625)
6. Thomas X, Olteanu N, Charrin C., Lhéritier V, Magaud J.P., Fiere D. Acute lymphoblastic leukemia in the elderly: The Edouard Herriot Hospital experience. Am J Hematol. 2001; 67(2): 73-83.
7. Chessells JM, Hall E, Prentice H.G., Durrant J., Bailey CC, Richards SM. The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties. Leukemia. 1998; 12(4): 463-473. (Pubitemid 28197568)
8. Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004; 22(22): 4626-4631. (Pubitemid 41185131)
9. Mengis C, Aebi S, Tobler A., Dähler W, Fey MF. Assessment of differences in patient populations selected for excluded from participation in clinical phase III acute myelogenous leukemia trials. J Clin Oncol. 2003; 21(21): 3933-3939. (Pubitemid 46606206)
10. Gökbuget N., Hoelzer D, Arnold R., et al. Subtypes and treatment outcome in adult acute lymphoblastic leukemia (ALL) < > 55 yrs [abstract]. Hematol J. 2001; 1(Suppl. 1): 694a.
11. Moorman AV, Chilton L, Wilkinson J., Ensor HM, Bown N, Proctor SJ. A population-based cytogenetic study of adults with acute lymphoblastic leukemia. Blood. 2010; 115(2): 206-214.
12. Abdulwahab A, Sykes J, Kamel-Reid S, Chang H., Brandwein JM. Therapy-related acute lymphoblastic leukemia is more frequent than previously recognized and has a poor prognosis. Cancer. 2012; 118(16): 3962-3967.
13. Gökbuget N, Hartog MC, Dengler J, et al. First analysis of prognostic factors in elderly Ph/BCR-ABL negative ALL including comorbidity scores: different factors predict mortality and relapse [abstract]. Onkologie. 2008; 31(Suppl. 4): 14(V29).
14. Offidani M, Corvatta L, Malerba L., et al. Comparison of two regimens for the treatment of elderly patients with acute lymphoblastic leukaemia (ALL) [abstract]. Blood. 2004; 104(11). Abstract 4490.
15. Robak T. Acute lymphoblastic leukaemia in elderly patients: biological characteristics and therapeutic approaches. Drugs Aging. 2004; 21(12): 779-791. (Pubitemid 39423334)
16. Pallis AG, Wedding U, Lacombe D., Soubeyran P, Wildiers H. Questionnaires and instruments for a multidimensional assessment of the older cancer patient: what clinicians need to know? Eur J Cancer. 2010; 46(6): 1019-1025.
17. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol. 2007; 25(14): 1824-1831. (Pubitemid 46860271)
18. Rodin MB, Mohile SG. A practical approach to geriatric assessment in oncology. J Clin Oncol. 2007; 25(14): 1936-1944. (Pubitemid 46854429)
19. Winkelmann N, Petersen I, Kiehntopf M., Fricke HJ, Hochhaus A, Wedding U. Results of comprehensive geriatric assessment effect survival in patients with malignant lymphoma. J Cancer Res Clin Oncol. 2011; 137(4): 733-738.
20. Tucci A, Ferrari S, Bottelli C., Borlenghi E, Drera M, Rossi G. A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. Cancer. 2009; 115(19): 4547-4553.
21. Ingram SS, Seo PH, Martell R.E., Clipp EC, Doyle ME, Montana GS, Cohen HJ. Comprehensive assessment of the elderly cancer patient: the feasibility of self-report methodology. J Clin Oncol. 2002; 20(3): 770-775. (Pubitemid 34111385)
22. Hurria A, Gupta S, Zauderer M., et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer. 2005; 104(9): 1998-2005. (Pubitemid 41513186)
23. Hurria A, Cirrincione CT, Muss H.B., et al. Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol. 2011; 29(10): 1290-1296.
24. Rowe JM, Buck G, Burnett A.K., et al.; ECOG; MRC/NCRI Adult Leukemia Working Party. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005; 106(12): 3760-3767. (Pubitemid 41739010)
25. Rousselot P, Delannoy A. Optimal pharmacotherapeutic management of acute lymphoblastic leukaemia in the elderly. Drugs Aging. 2011; 28(9): 749-764.
26. Gökbuget N., Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Semin Hematol. 2009; 46(1): 64-75.
27. Gökbuget N., Kneba M, Raff T., et al.; German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood. 2012; 120(9): 1868-1876.
28. Gökbuget N., Beck J, Brüggemann M, et al. Moderate intensive chemotherapy including CNS-prophylaxis with liposomal cytarabine is feasible and effective in older patients with Ph-negative acute lymphoblastic leukemia (ALL): results of a prospective trial from the German Multicenter Study Group for Adult ALL (GMALL) [abstract]. Blood. 2012; 120. Abstract 1493.
29. Giles FJ, Borthakur G, Ravandi F., et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol. 2007; 136(4): 624-627. (Pubitemid 46148199)
30. Walter RB, Othus M, Borthakur G., et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol. 2011; 29(33): 4417-4423.
31. Krug U, Röllig C, Koschmieder A., et al.; German Acute Myeloid Leukaemia Cooperative Group; Study Alliance Leukemia Investigators. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet. 2010; 376(9757): 2000-2008.
32. Tam-McDevitt J. Polypharmacy, aging, and cancer. Oncology (Williston Park). 2008; 22(9): 1052-1055, discussion 1055, 1058, 1060.
33. Puts MT, Monette J, Girre V., Costa-Lima B, Wolfson C, Batist G., Bergman H. Potential medication problems in older newly diagnosed cancer patients in Canada during cancer treatment: a prospective pilot cohort study. Drugs Aging. 2010; 27(7): 559-572.
34. Lees J, Chan A. Polypharmacy in elderly patients with cancer: clinical implications and management. Lancet Oncol. 2011; 12(13): 1249-1257.
35. Hurria A, Lichtman SM. Clinical pharmacology of cancer therapies in older adults. Br J Cancer. 2008; 98(3): 517-522. (Pubitemid 351214530)
36. Hurria A, Togawa K, Mohile S.G., et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011; 29(25): 3457-3465.
37. Extermann M, Boler I, Reich R.R., et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012; 118(13): 3377-3386.
38. Späth-Schwalbe E., Heil G, Heimpel H. Acute lymphoblastic leukemia in patients over 59 years of age. Experience in a single center over a 10-year period. Ann Hematol. 1994; 69(6): 291-296. (Pubitemid 24365609)
39. Sive JI, Buck G, Fielding A., et al. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. Br J Haematol. 2012; 157(4): 463-471.
40. Juliusson G, Karlsson K, Hallböök H. Population-based analyses in adult acute lymphoblastic leukemia. Blood. 2010; 116(6): 1011, author reply 1012.
41. Ferrari A, Annino L, Crescenzi S., Romani C, Mandelli F. Acute lymphoblastic leukemia in the elderly: results of two different treatment approaches in 49 patients during a 25-year period. Leukemia. 1995; 9(10): 1643-1647.
42. Toft N, Schmiegelow K, Klausen T.W., Birgens H. Adult acute lymphoblastic leukaemia in Denmark. A national population-based retrospective study on acute lymphoblastic leukaemia in Denmark 1998-2008. Br J Haematol. 2012; 157(1): 97-104.
43. Taylor PR, Reid MM, Proctor SJ. Acute lymphoblastic leukaemia in the elderly. Leuk Lymphoma. 1994; 13(5-6): 373-380. (Pubitemid 24158956)
44. Delannoy A, Ferrant A, Bosly A., et al. Acute lymphoblastic leukemia in the elderly. Eur J Haematol. 1990; 45(2): 90-93. (Pubitemid 20310110)
45. Nagura E, Minami S, Nagata K., et al. [Analysis of elderly patients, aged 60 years old or over, with acute lymphoblastic leukemia]. Nippon Ronen Igakkai Zasshi. 1999; 36(1): 52-58. (Pubitemid 29197714)
46. Onciu M, Lai R, Kantarjian H., Ball G, Smith T, Buesco-Ramos C. Acute lymphoblastic leukemia (ALL) in the elderly - the significance of the philadelphia chromosome [abstract]. Blood. 2000; 96(11). Abstract 4558.
47. Kantarjian HM, O'Brien S, Smith T, et al. Acute lymphocytic leukaemia in the elderly: characteristics and outcome with the vincristine-adriamycin- dexamethasone (VAD) regimen. Br J Haematol. 1994; 88(1): 94-100. (Pubitemid 24293858)
48. Mandelli F, Annino L, Ferrari A; for the GG. ALL in elderly: The GIMEMA trials [abstract]. Ann Hematol. 1995; 70(S2): 41a.
49. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000; 18(3): 547-561. (Pubitemid 30078536)
50. Todeschini G, Tecchio C, Meneghini V., et al. Acute lymphoblastic leukemia (ALL) in elderly patients receiving intensive treatment. Experience in 26 consecutive patients [abstract]. Blood. 1996; 88(Suppl 1). Abstract 170.
51. Bassan R, Di Bona E, Lerede T, et al. Age-adapted moderate-dose induction and flexible outpatient postremission therapy for elderly patients with acute lymphoblastic leukemia. Leuk Lymphoma. 1996; 22(3-4): 295-301. (Pubitemid 26318719)
52. Delannoy A, Sebban C, Cony-Makhoul P, et al.; French Group for Treatment of Adult Acute Lymphoblastic Leukemia. Age-adapted induction treatment of acute lymphoblastic leukemia in the elderly and assessment of maintenance with interferon combined with chemotherapy. A multicentric prospective study in forty patients. Leukemia. 1997; 11(9): 1429-1434.
53. Sancho JM, Ribera JM, Xicoy B, et al.; PETHEMA Group. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. Eur J Haematol. 2007; 78(2): 102-110. (Pubitemid 46058871)
54. Kao S, Xu W, Gupta V., et al. Outcome of patients aged 60 and over with acute lymphoblastic leukemia (ALL) treated with a modified pediatric protocol [abstract]. Blood. 2008; 112. Abstract 3962.
55. Gökbuget N, Leguay T, Hunault M, et al. First European chemotherapy schedule for elderly patients with acute lymphoblastic leukemia: promising remission rate and feasible moderate dose intensity consolidation [abstract]. Blood. 2008; 112(11). Abstract 304.
56. Hunault-Berger M., Leguay T, Thomas X., et al.; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL). A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study. Haematologica. 2011; 96(2): 245-252.
57. Annino L, Ferrari A, Elia L., et al. Clinical and hematological characteristics of adult acute lymphoblastic leukemia (ALL) with ALL-1 gene rearrangements[abstract]. Blood. 1995; 86(S1). Abstract 173.
58. Gökbuget N, Mueller HJ, Berger U, et al. Effectivity and toxicity of PEG-L-Asparaginase as part of a multidrug induction regimen in a multicenter trial in adult ALL [abstract]. Blood. 2000; 96(11). Abstract 3111.
59. Gökbuget N, de Wit M, Gerhardt A, et al. Results of a shortened, dose reduced treatment protocol in elderly patients with acute lymphoblastic leukemia (ALL) [abstract]. Blood. 2000; 96(11). Abstract 3104.
60. Larson RA, Dodge RK, Burns C.P., et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995; 85(8): 2025-2037.
61. van Schie R.M., Brüggemann RJ, Hoogerbrugge P.M., te Loo DM. Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia. J Antimicrob Chemother. 2011; 66(8): 1853-1856.
62. Sekeres MA, Elson P, Kalaycio M.E., et al. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood. 2009; 113(1): 28-36.
63. Bertoli S, Berard E, Huguet F., et al. Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. Blood. 2013. Prepublished on 2013/02/01 as DOI 10.1182/blood-2012-09-454553.
64. Delannoy A, Cazin B, Thomas X., et al.; LALA Group, France and Belgium. Treatment of acute lymphoblastic leukemia in the elderly: an evaluation of interferon alpha given as a single agent after complete remission. Leuk Lymphoma. 2002; 43(1): 75-81. (Pubitemid 34223973)
65. Gökbuget N. Treatment recommendation of the European working group for adult ALL, 1st ed. Unimed Science; 2011, Bremen.
66. Schwartz P, Hunault-Berger M, Chevallier P., et al. French results with the EWALL chemotherapy backbone in older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. AGRAALL report [abstract]. Haematologica. 2013; 98(S1): 463. Abstract S1124.
67. Delannoy A, Delabesse E, Lhéritier V, et al. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. Leukemia. 2006; 20(9): 1526-1532. (Pubitemid 44264094)
68. Ottmann OG, Wassmann B, Pfeifer H., et al.; GMALL Study Group. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Cancer. 2007; 109(10): 2068-2076. (Pubitemid 46745234)
69. Pfeifer H, Wettner C, Wassmann B., et al. Long term follow-up of 121 elderly patients with Philadelphia-positive acute lymphoblastic leukaemia (Ph+ALL) treated in prospective GMALL trials supports a greater emphasis on allogeneic SCT as definitive postremission therapy [abstract]. Blood. 2012; (102). Abstract 2608.
70. Vignetti M, Fazi P, Cimino G., et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood. 2007; 109(9): 3676-3678. (Pubitemid 46641715)
71. Foà R, Vitale A, Vignetti M, et al; GIMEMA Acute Leukemia Working Party. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011; 118(25): 6521-6528.
72. Papayannidis C, Fazi P, Piciocchi A., et al. Treating Ph + acute lymphoblastic leukemia (ALL) in the elderly: the sequence of two tyrosine kinase inhibitors (TKI) (nilotinib and imatinib) does not prevent mutations and relapse [abstract]. Blood. 2012; 102. Abstract 2601.
73. Rousselot P, Coudé MM, Huguet F, et al. Dasatinib (Sprycel®) and low intensity chemotherapy for first-line treatment in patients with de novo Philadelphia positive ALL aged 55 and over: final results of the EWALL-Ph-01 Study [abstract]. Blood. 2012; 120. Abstract 666.
74. Patel SB, Gojo I, Tidwell M.L., Sausville EA, Baer MR. Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy. Leuk Lymphoma. 2011; 52(7): 1211-1214.
75. Bassan R. Optimal central nervous system prophylaxis in Philadelphia chromosome-positive acute lymphoblastic leukemia: collateral damage in the imatinib era? Leuk Lymphoma. 2011; 52(7): 1164-1165.
76. Martino R, Giralt S, Caballero M.D., et al. Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study. Haematologica. 2003; 88(5): 555-560. (Pubitemid 36648445)
77. Arnold R, Massenkeil G, Bornhäuser M, et al. Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease. Leukemia. 2002; 16(12): 2423-2428. (Pubitemid 36054377)
78. Hamaki T, Kami M, Kanda Y., et al. Reduced-intensity stem-cell transplantation for adult acute lymphoblastic leukemia: a retrospective study of 33 patients. Bone Marrow Transplant. 2005; 35(6): 549-556. (Pubitemid 40450452)
79. Mohty M, Labopin M, Volin L., et al.; Acute Leukemia Working Party of EBMT. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2010; 116(22): 4439-4443.
80. Marks DI, Wang T, Pérez WS, et al. The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. Blood. 2010; 116(3): 366-374.
81. Ram R, Storb R, Sandmaier B.M., et al. Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia. Haematologica. 2011; 96(8): 1113-1120.
82. Hoelzer D, Gökbuget N. Chemoimmunotherapy in acute lymphoblastic leukemia. Blood Rev. 2012; 26(1): 25-32.
83. Hoelzer D, Huettmann A, Kaul F., et al. Immunochemotherapy with rituximab improves molecular CR rate and outcome in CD20+ B-lineage standard and high risk patients; results of 263 CD20+ patients studied prospectively in GMALL study 07/2003 [abstract]. Blood. 2010; 116. Abstract 170.
84. Thomas DA, O'Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010; 28(24): 3880-3889.
85. Bargou R, Leo E, Zugmaier G., et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008; 321(5891): 974-977.
86. Topp MS, Kufer P, Gökbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011; 29(18): 2493-2498.
87. Topp MS, Gökbuget N, Zugmaier G., et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012; 120(26): 5185-5187.
88. Topp M, Goekbuget N, Zugmaier G., et al. Anti-CD19 bite blinatumomab nduces high complete remission rate and prolongs overall survival in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) [abstract]. Blood. 2012; 120. Abstract 670.
89. Kantarjian H, Thomas D, Jorgensen J., et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012; 13(4): 403-411.
90. Gökbuget N, Basara N, Baurmann H, et al. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. Blood. 2011; 118(13): 3504-3511.
91. Gökbuget N, Hartog CM, Bassan R, et al; German Multicenter Study Group for Adult ALL and the European Working Group for Adult ALL. Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma. Haematologica. 2011; 96(2): 238-244.
92. O'Brien S., Schiller G, Lister J., et al. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol. 2013; 31(6): 676-683.
93. Pui CH, Mullighan CG, Evans W.E., Relling MV. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood. 2012; 120(6): 1165-1174.
94. Turner NJ, Haward RA, Mulley G.P., Selby PJ. Cancer in old age - is it inadequately investigated and treated? BMJ. 1999; 319(7205): 309-312. (Pubitemid 29353951)
95. Juliusson G; Swedish AML Group. Most 70- to 79-year-old patients with acute myeloid leukemia do benefit from intensive treatment. Blood. 2011; 117(12): 3473-3474.
96. Juliusson G, Antunovic P, Derolf A., et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009; 113(18): 4179-4187.
97. Löwenberg B., Zittoun R, Kerkhofs H., et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol. 1989; 7(9): 1268-1274. (Pubitemid 19220128)
98. Pulte D, Gondos A, Brenner H. Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood. 2009; 113(7): 1408-1411.